European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Leslie Tari, PhD, discusses Cidara Therapeutics' Cloudbreak antiviral initiatives.

Will biomarker-guided specific therapies the best option for treating sepsis in the future?

During a year-long study, 80 electronic conversational comments were made using the stewardship team’s audit-and-feedback tool and recommendations were fully adopted 90% of the time.

Oral ibrexafungerp demonstrates a favorable therapeutic response in patients with difficult-to-treat Candida infections, including those caused by non-albicans Candida species.

Lefamulin demonstrated non-inferiority when compared with moxifloxacin, and both treatment arms reported a low rate of serious treatment-emergent AEs or treatment-emergent AEs leading to discontinuation.

Cidara Therapeutics has developed CB-012, a stable conjugate of a highly potent antiviral agent linked to human IgG1 Fc, and investigators are evaluating the asset for the treatment and prevention of seasonal and pandemic influenza A and B infections.

The ASPECT-NP trial compared a new 3-gram dose regimen of ceftolozane/tazobactam versus meropenem in the treatment of ventilated nosocomial pneumonia.

Investigators found increased mortality in the combination arm where 21% of patients died vs 16% in the standard therapy arm, although the number of patients with persistent bacteremia at day 5 in the combination arm was significantly reduced compared with standard therapy.

A study found that the molecule, Compound A, has potent activity against Acinetobacter Pneumonia in mice possibly by a dual killing mechanism and by reducing lipopolysaccharide-induced vascular leak.

Rezafungin achieved greater and more prolonged penetration at sites of intra-abdominal candidiasis than micafungin, which correlates with significantly greater activity against FKS-mutant Candida glabrata clinical strains.

A study found that eracavycline was 2-4-fold more active than tigecycline against isolates that produced ESBL and at least 8-fold more active than tigecycline against A baumannii.

Investigators detail the activity of cefiderocol, a novel parenteral siderophore cephalosporin, against carbapenem-resistant clinical isolates.

An Italian study found that immunization rates are high among health workers, but an important proportion of employees are not immune to mumps.

In a study of hospitalized patients across Europe, oritavancin (MIC50/MIC90, 0.03/0.06 mg/L) inhibited all S aureus isolates at ≤0.12 mg/L (susceptible breakpoint).

Ignacio Martin-Loeches, MD, PhD, discusses the efficacy outcomes of the ASPECT-NP trial evaluating ceftolozane/tazobactam for the treatment of nosocomial pneumonia.

What is the key to success that helped a Spanish hospital achieve an 80% reduction in global incidence of catheter-related bloodstream infections and sustain it over an 8-year period?

Jose Arribas, MD, discusses the challenges in the field of long-acting injectable therapy for the treatment, management, and even prevention of HIV.

A large percentage (96%) of health care worker respondents reported feeling confident in their knowledge of antibiotic resistance, but only 60% answered the 7 key questions correctly.

In a symposium at ECCMID 2019, Giovanni Rezza, MD, highlighted the growth of tropical outbreaks occurring in Europe and discussed how warmer temperatures may lead to more frequent tropical outbreaks.

After receiving treatment with ibrexafungerp, a patient with esophageal candidiasis gradually improved and by day 54 he was completely asymptomatic.

Investigators on the CapU3 study concluded that urinary HPV testing may be a good alternative to Pap smear for some women.

An 18-year retrospective cohort study of 130 hospitals in the US Veterans Health Administration system revealed a significant reduction in cases of hospital-onset candidemia. But what caused the drop?

A new study has uncovered that only one-third of patients who present to the emergency department with suspected UTI have evidence of infection, yet the majority receive antibiotics.

MDROs were detected in 334 (22%) curtain cultures from 6 skilled nursing facilities in southeast Michigan.

Contagion® will be heading to Amsterdam, Netherlands, on Saturday, April 13, 2019, to report on the annual European Congress of Clinical Microbiology and Infectious Diseases conference.

The drug met its primary endpoint of noninferiority to vancomycin at both 48 to 72 hours after drug initiation and test of cure.

Data from the IGNITE4 phase 3 trial supports the use of eravacycline for the treatment of complicated intra-abdominal infections (cIAI), including infections caused by pathogens resistant to other antibiotics.

An outbreak of infections caused by the drug-resistant fungus, Candida auris, in one United Kingdom hospital has been linked to multi-use patient equipment.

Investigational beta-lacatamase inhibitor IMI/REL demonstrates a favorable overall response against certain imipenem-non-susceptible bacterial infections.

Researchers present positive new data from multiple studies of VIBATIV at the 2018 ECCMID conference in Madrid, Spain.